Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129473 | 0.86 | MAOB (0.38) | TSHRMAOBMAOABCHEACHE | |
| SCHEMBL135836 | 0.72 | — | — | |
| SCHEMBL7063876 | 0.69 | TSHR (0.63) | TSHRMAOBCYP2A6MAOACA12 | |
| SCHEMBL24774025 | 0.67 | TSHR (0.60) | TSHRMAOBCYP2A6MAOACA12 | |
| SCHEMBL11328700 | 0.67 | TSHR (0.60) | TSHRMAOBCYP2A6MAOABCHE | |
| SCHEMBL24772918 | 0.67 | TSHR (0.60) | TSHRMAOBCYP2A6MAOACA12 | |
| Fluoride SCHEMBL9776698 | 0.67 | TSHR (0.80) | TSHRMAOBCYP2A6MAOAMAPT | |
| Fluoride SCHEMBL27822924 | 0.67 | TSHR (0.80) | TSHRMAOBCYP2A6MAOAMAPT | |
| SCHEMBL452179 | 0.67 | TSHR (0.46) | TSHRMAOBCYP2A6MAOAKDM1A | |
| SCHEMBL7065615 | 0.65 | TSHR (0.57) | TSHRMAOBCYP2A6MAOACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | claimed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | claimed |
| EP-3227300-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-10-11 | — | — | EP | claimed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | claimed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | claimed |
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | claimed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | claimed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | claimed |
| EP-2134342-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-4638000-A | HYPOTENSIVES, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | claimed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | claimed |
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-3227300-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-4591458-A | ENZYME INHIBITORS; HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-05-27 | — | — | US | disclosed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0156455-A2 | Condensed seven-membered ring compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0135349-A1 | Condensed seven-membered ring compounds and their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | TSHR 875/4885MAOB 247/4885CYP2A6 53/4885 |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | TSHR 725/4885MAOB 536/4885CYP2A6 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.